BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (Company or Inozyme), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (the Company or Inozyme), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Inozyme to Report Data from Ongoing Phase 1/2 Trials of INZ-701
Inozyme Pharma Reports Full Year 2023 Financial Results
BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (œCompany or œInozyme), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (Company or Inozyme), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (Company€ or Inozyme€), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (œInozyme or the œCompany), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 Topline data readouts from ongoing Phase 1/2...